Table 2. The proportion of metastatic pattern of HER-2 negative breast cancer stratified by subtypes*.
| ER+/PR+ | ER+/PR− | ER−/PR+ | ER−/PR− | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (N=5,066) | % | (N=1,118) | % | (N=93) | % | (N=1,449) | % | ||||
| One site | |||||||||||
| Bone | 2,767 | 54.62 | 540 | 48.30 | 13 | 13.98 | 360 | 24.84 | |||
| Viscera | 666 | 13.15 | 192 | 17.17 | 39 | 41.94 | 541 | 37.34 | |||
| Multi-sites | |||||||||||
| Bone + one site of viscera | 1,153 | 22.76 | 257 | 22.99 | 22 | 23.66 | 265 | 18.29 | |||
| ≥ Two sites of viscera | 480 | 9.47 | 129 | 11.54 | 19 | 20.43 | 283 | 19.53 | |||
Viscera including liver, brain or lung. *, P values were calculated among all groups using a chi-squared test and P<0.001. ER, estrogen receptor; PR, progesterone receptor.